Context: There is a paucity of any significant data on the estrogen receptor (ER), Progesterone receptor (PR) and Her-2 receptor status of breast cancer patients from the eastern part of India.
Aims: This study aims to document the ER ,PR and Her-2 status of breast cancer patients in the south Indian population, as catered by a premier tertiary care hospital in Madurai.
Subjects and Methods: All breast cancer patients registered between January 1, 2016 and December 31, 2018, in the Department of Medical Oncology, of Government Rajaji Hospital, Madurai, who had at least undergone a core biopsy or surgery, were analyzed retrospectively for documentation of their ER PR and Her-2 status, using the 2010 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) interpretation guidelines.
Results: Over a period of 2 years, a total of 427 patients were included for the study. A total of 395 (92.5%) patients had their ER PR and Her-2 data available for evaluation. ER and PR positive was seen in 138 (32.5%) patients, ER and PR negative in 179 (42%) patients, ER positive and PR negative in 29 (6.7%) patients, and ER negative and PR positive results was found in 17 (3.98%) patients. Her-2 was positive in 89 patients (20.8%). Triple Negative status was seen in 158 patients (37%)
Conclusions: This is one of the first single-institutional documentation of ER, PR and Her-2 status from southern India, having a modest number of patients and one of the earliest documentations using the latest ASCO/CAP interpretation guidelines. These findings resemble the data from other parts of India and also reiterate the fact that majority of the Indian breast cancer patients are still ER and PR negative and close to 40% of them are Triple-negative which carries a poor prognosis.
Impact Factor
2022: 6.012
This work is licensed under a